MDPI and ACS Style
Gal, J.; Milano, G.; Brest, P.; Ebran, N.; Gilhodes, J.; Llorca, L.; Dubot, C.; Romieu, G.; Desmoulins, I.; Brain, E.;
et al. VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals 2020, 13, 414.
https://doi.org/10.3390/ph13110414
AMA Style
Gal J, Milano G, Brest P, Ebran N, Gilhodes J, Llorca L, Dubot C, Romieu G, Desmoulins I, Brain E,
et al. VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study. Pharmaceuticals. 2020; 13(11):414.
https://doi.org/10.3390/ph13110414
Chicago/Turabian Style
Gal, Jocelyn, Gérard Milano, Patrick Brest, Nathalie Ebran, Julia Gilhodes, Laurence Llorca, Coraline Dubot, Gilles Romieu, Isabelle Desmoulins, Etienne Brain,
and et al. 2020. "VEGF-Related Germinal Polymorphisms May Identify a Subgroup of Breast Cancer Patients with Favorable Outcome under Bevacizumab-Based Therapy—A Message from COMET, a French Unicancer Multicentric Study" Pharmaceuticals 13, no. 11: 414.
https://doi.org/10.3390/ph13110414